- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dexmedetomidine Shows Promise in Reducing Postoperative PTSD in Trauma Patients
Posttraumatic stress disorder (PTSD) is a common psychological condition that affects individuals who have experienced trauma, including those who undergo surgery. However, a recent study published in JAMA Network Open has shed light on a potential preventive measure. Researchers have found that the administration of low-dose intravenous dexmedetomidine during and after emergency surgery can significantly reduce the occurrence of PTSD in trauma patients. These findings offer hope for improving the mental health outcomes of individuals recovering from traumatic experiences.
The study, a double-blind, randomized clinical trial, was conducted by Ypujia Yu and team at four hospital centres in Jiangsu Province, China. It included 310 patients who underwent emergency surgery following trauma. The participants were divided into two groups: one received dexmedetomidine, while the other received a placebo (normal saline).
The primary outcome measure was the difference in the incidence of PTSD one month after surgery, evaluated using the Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (CAPS-5). Secondary outcomes included pain scores within 48 hours and one month postoperatively, postoperative delirium, nausea, pruritus, subjective sleep quality, anxiety, and occurrence of adverse events.
● The results of the trial demonstrated encouraging findings. One month after surgery, the incidence of PTSD was significantly lower in the dexmedetomidine group compared to the control group (14.1% vs. 24.0%; P = .03).
● Additionally, patients who received dexmedetomidine had significantly lower CAPS-5 scores, indicating reduced severity of PTSD symptoms (17.3 [5.3] vs. 18.9 [6.6]; mean difference, 1.65; 95% CI, 0.31-2.99; P = .02).
● After adjusting for potential confounders, the patients in the dexmedetomidine group were found to be significantly less likely to develop PTSD compared to the control group one month postoperatively (adjusted odds ratio, 0.51; 95% CI, 0.27-0.94; P = .03).
The results of this study highlight the potential of dexmedetomidine in reducing the incidence and severity of postoperative PTSD in trauma patients. By incorporating this medication during and after emergency surgery, healthcare professionals may enhance patients' psychological recovery and improve their overall well-being. Further research is necessary to explore the underlying mechanisms through which dexmedetomidine influences fear memory consolidation and the development of PTSD. Additionally, future JAMA Network Openstudies should examine the effectiveness of dexmedetomidine in larger populations and different types of surgical procedures.
The findings of this groundbreaking study indicate that the administration of intraoperative and postoperative dexmedetomidine significantly reduces the incidence of PTSD among trauma patients undergoing emergency surgery. This discovery holds significant promise for improving the mental health outcomes of individuals recovering from traumatic experiences. By addressing both the physical and psychological aspects of trauma, healthcare providers
can enhance the overall recovery process for patients undergoing surgery after trauma. The study's results warrant further investigation into the potential applications of dexmedetomidine in preventing postoperative psychiatric complications and emphasize the importance of a holistic approach to patient care.
Reference:
Yu, Y., Li, Y., Han, D., Gong, C., Wang, L., Li, B., Yao, R., & Zhu, Y. (2023). Effect of dexmedetomidine on posttraumatic stress disorder in patients undergoing emergency trauma surgery: A randomized clinical trial. JAMA Network Open, 6(6), e2318611. https://doi.org/10.1001/jamanetworkopen.2023.18611
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751